In PLOS this week: sequencing-based way to uncover drug resistance in tuberculosis bacteria, genetic population structure of mosquito vectors, and more.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
Exposure to DNA-damaging cancer treatments affects mutational signatures found in advanced and metastatic cancers, with alterations possibly indicating drug resistance.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Blood and skin cell transcriptomes revealed a JAK-STAT signaling and human herpesvirus targets in an individual with refractory drug-induced hypersensitivity syndrome.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
